Cargando…
Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis
In current international classification systems (ICD-10, DSM5), the diagnostic criteria for psychotic disorders (e.g. schizophrenia and schizoaffective disorder) are based on symptomatic descriptions since no unambiguous biomarkers are known to date. However, when underlying causes of psychotic symp...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010098/ https://www.ncbi.nlm.nih.gov/pubmed/33785807 http://dx.doi.org/10.1038/s41598-021-86170-w |
_version_ | 1783672990882332672 |
---|---|
author | Rattay, Tim W. Martin, Pascal Vittore, Debora Hengel, Holger Cebi, Idil Tünnerhoff, Johannes Stefanou, Maria-Ioanna Hoffmann, Jonatan F. von der Ehe, Katrin Klaus, Johannes Vonderschmitt, Julia Herrmann, Matthias L. Bombach, Paula Al Barazi, Hazar Zeltner, Lena Richter, Janina Hesse, Klaus Eckstein, Kathrin N. Klingberg, Stefan Wildgruber, Dirk |
author_facet | Rattay, Tim W. Martin, Pascal Vittore, Debora Hengel, Holger Cebi, Idil Tünnerhoff, Johannes Stefanou, Maria-Ioanna Hoffmann, Jonatan F. von der Ehe, Katrin Klaus, Johannes Vonderschmitt, Julia Herrmann, Matthias L. Bombach, Paula Al Barazi, Hazar Zeltner, Lena Richter, Janina Hesse, Klaus Eckstein, Kathrin N. Klingberg, Stefan Wildgruber, Dirk |
author_sort | Rattay, Tim W. |
collection | PubMed |
description | In current international classification systems (ICD-10, DSM5), the diagnostic criteria for psychotic disorders (e.g. schizophrenia and schizoaffective disorder) are based on symptomatic descriptions since no unambiguous biomarkers are known to date. However, when underlying causes of psychotic symptoms, like inflammation, ischemia, or tumor affecting the neural tissue can be identified, a different classification is used ("psychotic disorder with delusions due to known physiological condition" (ICD-10: F06.2) or psychosis caused by medical factors (DSM5)). While CSF analysis still is considered optional in current diagnostic guidelines for psychotic disorders, CSF biomarkers could help to identify known physiological conditions. In this retrospective, partly descriptive analysis of 144 patients with psychotic symptoms and available CSF data, we analyzed CSF examinations' significance to differentiate patients with specific etiological factors (F06.2) from patients with schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F2). In 40.3% of all patients, at least one CSF parameter was out of the reference range. Abnormal CSF-findings were found significantly more often in patients diagnosed with F06.2 (88.2%) as compared to patients diagnosed with F2 (23.8%, p < 0.00001). A total of 17 cases were identified as probably caused by specific etiological factors (F06.2), of which ten cases fulfilled the criteria for a probable autoimmune psychosis linked to the following autoantibodies: amphiphysin, CASPR2, CV2, LGl1, NMDA, zic4, and titin. Two cases presented with anti-thyroid tissue autoantibodies. In four cases, further probable causal factors were identified: COVID-19, a frontal intracranial tumor, multiple sclerosis (n = 2), and neurosyphilis. Twenty-one cases remained with "no reliable diagnostic classification". Age at onset of psychotic symptoms differed between patients diagnosed with F2 and F06.2 (p = 0.014), with the latter group being older (median: 44 vs. 28 years). Various CSF parameters were analyzed in an exploratory analysis, identifying pleocytosis and oligoclonal bands (OCBs) as discriminators (F06.2 vs. F2) with a high specificity of > 96% each. No group differences were found for gender, characteristics of psychotic symptoms, substance dependency, or family history. This study emphasizes the great importance of a detailed diagnostic workup in diagnosing psychotic disorders, including CSF analysis, to detect possible underlying pathologies and improve treatment decisions. |
format | Online Article Text |
id | pubmed-8010098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80100982021-04-01 Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis Rattay, Tim W. Martin, Pascal Vittore, Debora Hengel, Holger Cebi, Idil Tünnerhoff, Johannes Stefanou, Maria-Ioanna Hoffmann, Jonatan F. von der Ehe, Katrin Klaus, Johannes Vonderschmitt, Julia Herrmann, Matthias L. Bombach, Paula Al Barazi, Hazar Zeltner, Lena Richter, Janina Hesse, Klaus Eckstein, Kathrin N. Klingberg, Stefan Wildgruber, Dirk Sci Rep Article In current international classification systems (ICD-10, DSM5), the diagnostic criteria for psychotic disorders (e.g. schizophrenia and schizoaffective disorder) are based on symptomatic descriptions since no unambiguous biomarkers are known to date. However, when underlying causes of psychotic symptoms, like inflammation, ischemia, or tumor affecting the neural tissue can be identified, a different classification is used ("psychotic disorder with delusions due to known physiological condition" (ICD-10: F06.2) or psychosis caused by medical factors (DSM5)). While CSF analysis still is considered optional in current diagnostic guidelines for psychotic disorders, CSF biomarkers could help to identify known physiological conditions. In this retrospective, partly descriptive analysis of 144 patients with psychotic symptoms and available CSF data, we analyzed CSF examinations' significance to differentiate patients with specific etiological factors (F06.2) from patients with schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F2). In 40.3% of all patients, at least one CSF parameter was out of the reference range. Abnormal CSF-findings were found significantly more often in patients diagnosed with F06.2 (88.2%) as compared to patients diagnosed with F2 (23.8%, p < 0.00001). A total of 17 cases were identified as probably caused by specific etiological factors (F06.2), of which ten cases fulfilled the criteria for a probable autoimmune psychosis linked to the following autoantibodies: amphiphysin, CASPR2, CV2, LGl1, NMDA, zic4, and titin. Two cases presented with anti-thyroid tissue autoantibodies. In four cases, further probable causal factors were identified: COVID-19, a frontal intracranial tumor, multiple sclerosis (n = 2), and neurosyphilis. Twenty-one cases remained with "no reliable diagnostic classification". Age at onset of psychotic symptoms differed between patients diagnosed with F2 and F06.2 (p = 0.014), with the latter group being older (median: 44 vs. 28 years). Various CSF parameters were analyzed in an exploratory analysis, identifying pleocytosis and oligoclonal bands (OCBs) as discriminators (F06.2 vs. F2) with a high specificity of > 96% each. No group differences were found for gender, characteristics of psychotic symptoms, substance dependency, or family history. This study emphasizes the great importance of a detailed diagnostic workup in diagnosing psychotic disorders, including CSF analysis, to detect possible underlying pathologies and improve treatment decisions. Nature Publishing Group UK 2021-03-30 /pmc/articles/PMC8010098/ /pubmed/33785807 http://dx.doi.org/10.1038/s41598-021-86170-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Rattay, Tim W. Martin, Pascal Vittore, Debora Hengel, Holger Cebi, Idil Tünnerhoff, Johannes Stefanou, Maria-Ioanna Hoffmann, Jonatan F. von der Ehe, Katrin Klaus, Johannes Vonderschmitt, Julia Herrmann, Matthias L. Bombach, Paula Al Barazi, Hazar Zeltner, Lena Richter, Janina Hesse, Klaus Eckstein, Kathrin N. Klingberg, Stefan Wildgruber, Dirk Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title | Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title_full | Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title_fullStr | Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title_full_unstemmed | Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title_short | Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
title_sort | cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010098/ https://www.ncbi.nlm.nih.gov/pubmed/33785807 http://dx.doi.org/10.1038/s41598-021-86170-w |
work_keys_str_mv | AT rattaytimw cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT martinpascal cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT vittoredebora cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT hengelholger cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT cebiidil cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT tunnerhoffjohannes cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT stefanoumariaioanna cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT hoffmannjonatanf cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT vonderehekatrin cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT klausjohannes cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT vonderschmittjulia cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT herrmannmatthiasl cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT bombachpaula cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT albarazihazar cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT zeltnerlena cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT richterjanina cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT hesseklaus cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT ecksteinkathrinn cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT klingbergstefan cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis AT wildgruberdirk cerebrospinalfluidfindingsinpatientswithpsychoticsymptomsaretrospectiveanalysis |